- Home
- GNLX vs APLT Comparison
GNLX vs APLT Comparison
Compare GNLX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- APLT
- Stock Information
- Founded
- GNLX 2001
- APLT 2016
- Country
- GNLX United States
- APLT United States
- Employees
- GNLX N/A
- APLT N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- APLT Health Care
- Exchange
- GNLX Nasdaq
- APLT Nasdaq
- Market Cap
- GNLX 128.0M
- APLT 63.6M
- IPO Year
- GNLX 2023
- APLT 2019
- Fundamental
- Price
- GNLX $3.84
- APLT $0.43
- Analyst Decision
- GNLX Strong Buy
- APLT Buy
- Analyst Count
- GNLX 4
- APLT 6
- Target Price
- GNLX $17.75
- APLT $6.10
- AVG Volume (30 Days)
- GNLX 132.9K
- APLT 876.2K
- Earning Date
- GNLX 11-13-2025
- APLT 11-06-2025
- Dividend Yield
- GNLX N/A
- APLT N/A
- EPS Growth
- GNLX N/A
- APLT N/A
- EPS
- GNLX N/A
- APLT N/A
- Revenue
- GNLX N/A
- APLT $121,000.00
- Revenue This Year
- GNLX N/A
- APLT N/A
- Revenue Next Year
- GNLX N/A
- APLT $5,931.24
- P/E Ratio
- GNLX N/A
- APLT N/A
- Revenue Growth
- GNLX N/A
- APLT N/A
- 52 Week Low
- GNLX $1.95
- APLT $0.30
- 52 Week High
- GNLX $5.89
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- GNLX 58.54
- APLT 40.76
- Support Level
- GNLX $3.56
- APLT $0.40
- Resistance Level
- GNLX $3.61
- APLT $0.46
- Average True Range (ATR)
- GNLX 0.23
- APLT 0.03
- MACD
- GNLX 0.03
- APLT -0.01
- Stochastic Oscillator
- GNLX 73.57
- APLT 18.05
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.